H.PIO Co., Ltd. (KOSDAQ:357230)
2,570.00
-165.00 (-6.03%)
At close: May 29, 2026
H.PIO Revenue
H.PIO had revenue of 63.31B KRW in the quarter ending March 31, 2026, with 14.09% growth. This brings the company's revenue in the last twelve months to 266.01B, up 10.92% year-over-year. In the year 2025, H.PIO had annual revenue of 258.19B with 6.32% growth.
Revenue (ttm)
266.01B
Revenue Growth
+10.92%
P/S Ratio
0.40
Revenue / Employee
3.50B
Employees
76
Market Cap
106.08B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 258.19B | 15.36B | 6.32% |
| Dec 31, 2024 | 242.83B | 10.80B | 4.66% |
| Dec 31, 2023 | 232.03B | 36.05B | 18.39% |
| Dec 31, 2022 | 195.98B | 36.54B | 22.92% |
| Dec 31, 2021 | 159.43B | 16.65B | 11.66% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ahn-Gook Pharmaceutical | 330.05B |
| DongKoo Bio & Pharma | 242.08B |
| Daehan Nupharm | 205.39B |
| HYUNDAI BIOLAND | 135.04B |
| WITHUS PHARMACEUTICAL Co.,LTD. | 108.89B |
| OPTUS Pharmaceutical | 91.62B |
| KOREA PHARMA | 91.42B |
| Sam-A Pharm. | 70.93B |